Anakinra targeted treatment adds efficacy toxicity in rheumatoid arthritis Cochrane systematic review reports lower efficacy than other targeted agents in this disease with some important toxicity problems.

Rheumatoid arthritis (RA) is an agonizing autoimmune disorder of uncertain origin leading to chronic inflammation at the joints. RA develops in three stages. Nearly 46 million Americans or more than 21 percent of the adult population are affected by this disorder. The origin of RA is unknown but the disease can be controlled by way of new drugs exercise joint protection skills and self-management techniques.

Rituximab shows efficacy in rheumatoid arthritis in randomized trials

Popular rheumatoid arthritis drugs which work by blocking a protein linked with inflammation have been shown to not raise the overall cancer risk according to new information from Spanish researchers released on Saturday. The medication in question known as TNF blockers suppress the immune system through a blockade of activity of an inflammatory protein known as tumor necrosis factor.

Dr. Ritu Khurana and her fellow researchers have determined that the risks of cancer are increased in the rheumatoid arthritic even after taking tobacco use and asbestos exposure into account. The rate of rhemuatoid arthritis was about 3.4 percent among the lung cancer patients in comparison to about 1.8 percent among the patients who did not have lung cancer the researchers report in the Journal of Rheumatology.

FDA: Actemra is a hit for rheumatoid arthritis IL-6 monoclonal shows good efficacy in randomized trial

Etanercept plus methotrexate superior in rheumatoid arthritis Randomized trial in Lancet this week